At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 83 enrolled
Drug / intervention
AZD5069 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy of 28-Day Oral Administration of AZD5069 Twice Daily in Patients With Bronchiectasis
In Brief
A Phase 2 clinical trial evaluating AZD5069 and Placebo for Bronchiectasis and 2 related conditions. Completed, enrolled 83 participants across 15 sites in 3 countries.
Detailed Summary
The purpose of this study is to investigate the effect of AZD5069 in patients with bronchiectasis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBronchiectasis, Lung Disease, Respiratory Diseases
CountriesCzechia, Poland, United Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedDec 2010
Enrollment StartFeb 2011
Primary CompletionFeb 2012
TodayJul 2026
First PostedDec 7, 2010
Enrollment StartFeb 1, 2011
Primary CompletionFeb 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 15.6 years ago
Interventions
AZD5069drug
Oral dose bid
Placebodrug
Oral dose bid